Ricerc@Sapienza

Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of patients that can be candidates for immunotherapy. In this pilot study, a cohort of 34 consecutive patients bearing programmed death-ligand 1 (PD-L1)-positive non-small cell lung carcinoma (NSCLC), treated with pembrolizumab, was considered.

Background: Italian consensus for the classification and reporting of thyroid cytology
(ICCRTC) has been used in almost all Italian institutions since 2014. High reliability
of ICCRTC in classifying low and high risk indeterminate nodules (Tir 3A and Tir 3B,
respectively) was demonstrated. Here we reviewed our casuistry of thyroid indeterminate
lesions to analyze the histologic outcome.
Methods: All lesions undergone FNA and final histology at S. Andrea Hospital of Rome